Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 9, 2013, Pages

  Schoot, Reineke A ^a   Kremer, Leontien C M ^a   van de Wetering, Marianne D ^a   van Ommen, Cornelia H ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ENOXAPARIN; FRESH FROZEN PLASMA; HEMOGLOBIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT ANTITHROMBIN III; REVIPARIN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 8; CRYOPRECIPITATE COAGULUM; FIBRINOGEN;

ABDOMINAL BLEEDING; ANTITHROMBIN DEFICIENCY; BLEEDING; BRAIN HEMORRHAGE; CATHETER INFECTION; CATHETER REMOVAL; CHILDHOOD CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FIBRINOGEN DEFECT; HEMARTHROSIS; HEMATURIA; HUMAN; INJECTION SITE CONTUSION; LOW DRUG DOSE; LUNG HEMORRHAGE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; RETROPERITONEAL HEMORRHAGE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; WOUND HEMORRHAGE; CENTRAL VENOUS CATHETER; CHILD; NEOPLASM; PLASMA; COMPLICATION;

ANTICOAGULANTS; ANTITHROMBINS; CENTRAL VENOUS CATHETERS; CHILD; CONTROLLED CLINICAL TRIALS AS TOPIC; FACTOR VIII; FIBRINOGEN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PLASMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84899466805     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009160.pub2     Document Type: Review

References (121)

1. Abbott LS, Deevska M, Fernandez CV, Dix D, Price VE, Wang H, et al.The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 2009;114:5146-51.
2. Elhasid R, Lanir N, Sharon R, Weyl Ben Arush M, Levin C, Postovsky S, et al.Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagulation and Fibrinolysis 2001;12:367-70.
3. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al.An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research 2003;109:101-8.
4. Meister B, Kropshofer G, Klein Franke A, Strasak AM, Hager J, Streif W. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatric Blood & Cancer 2008;50:298-303.
5. Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J, et al.Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Thrombosis and Haemostasis. Germany, 2003; Vol. 90:235-44.
6. Ruud E, Holmstrom H, De Lange C, Hogstad EM, Wesenberg F. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignanciesa randomized, controlled study. Acta Paediatrica 2006;95:1053-9.
7. Abdelkefi A, Ladeb S, Ben OT, Torjman L, Jeddi R, Ben AH, et al.Indications and complications of central venous catheters in hematologic oncology: report of 81 cases. La Tunisie Medicale 2000;78:641-7.
8. Abdelkefi A, Ben Othman T, Kammoun L, Chelli M, Romdhane NB, Kriaa A, et al.Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. Thrombosis and Haemostasis 2004;92:654-61.
9. Abdelkefi A, Chelli M, Achour W, Ben Romdhane N, Torjman L, Ladeb S, et al.[Catheter related bloodstream infection in haematological patients: a prospective randomized study comparing heparin-coated with chlorhexidine and silver sulfadiazine impregnated central venous catheters]. Congress: American Society of Hematology annual meeting and exposition, ASH. 2008:1174.
10. Akl EA, Karmath G, Yosuico V, Kim SY, Barba M, Sperati F, et al.Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. Cochrane Database of Systematic Reviews 2008;2:Art. No.: CD006650. DOI: 10.1002/14651858.CD006650.pub2.
11. Andrew M, Marzinotto V, Pencharz P, Zlotkin S, Burrows P, Ingram J, et al.A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. Journal of Pediatrics 1995;126:358-63.
12. Athale U, Siciliano S, Cheng J, Thabane L, Chan AKC. [Decreased overall survival and increased risk of thrombosis in children with cancer and central venous line (CVL) dysfunction]. Conference: 41st Congress of the International Society of Pediatric Oncology, SIOP. 2009:850.
13. Athale U, Grace R, Min J, Hochberg J, Nayiager T, Taghzouti N, et al.[Management of thromboembolism in children and adolescents with acute lymphoblastic leukemia]. Conference: 42nd Congress of the International Society of Pediatric Oncology, SIOP. 2010:855.
14. Athale UH, Siciliano S, Cheng J, Thabane L, Chan AKC. Central venous line dysfunction is an independent predictor of poor survival in children with cancer. Journal of Pediatric Hematology/Oncology 2012;34(3):188-93.
15. Bagnall HA, Gomperts E, Atkinson JB. Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children. Pediatrics 1989;83:963-6.
16. Barzaghi A, Dell'Orto M, Rovelli A, Rizzari C, Colombini A, Uderzo C. Central venous catheter clots: incidence, clinical significance and catheter care in patients with hematologic malignancies. Pediatric Hematology and Oncology 1995;12:243-50.
17. Bohlin CW, Reardon DA, Desjardins A, Quinn JA, Rich JN, Bota DA, et al.[Tinzaparin prophylaxis in brain tumor patients]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2007:12506.
18. Buller HR. [A dose finding study of the oral direct factor XA inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosisThe Boticelli Investigators]. Conference: 22nd Congress of the International Society on Thrombosis and Haemostasis, ISTH. 2007:O-S-003.
19. Carrier M, Tay J, Fergusson D, Well PS. [Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review]. Congress: American Society of Hematology annual meeting and exposition, ASH. 2007:1875.
20. Cesaro S, Paris M, Corro R, Svaluto G, Zanon GF, Gamba P, et al.Successful treatment of a catheter-related right atrial thrombosis with recombinant tissue plasminogen activator and heparin. Supportive Care in Cancer 2002;10:253-5.
21. Cesaro S, Corro R, Gamba P, Zanon GF. Is there really a need for anti-coagulant prophylaxis for CVC-related thrombotic complications in pediatric oncological-hematological diseases?. Supportive Care in Cancer 2002;10:258-9.
22. Cesaro S, Tridello G, Cavaliere M, Magagna L, Gavin P, Cusinato R, et al.Prospective, randomized trial of two different modalities of flushing central venous catheters in pediatric patients with cancer. Journal of Clinical Oncology 2009;27:2059-65.
23. Chatzinikolaou I, Zipf TF, Hanna H, Umphrey J, Roberts WM, Sherertz R, et al.Minocycline-ethylenediaminetetraacetate lock solution for the prevention of implantable port infections in children with cancer. Clinical Infectious Diseases 2003;36:116-9.
24. Coleman EA, Anaissie EJ, Kennedy RL, Lockhart KD, Stewart CB, Bailey C. [Predictors of deep vein thrombosis (DVT) in newly diagnosed multiple myeloma (MM) patient with and without prophylactic recombinant erythropoietin (EPO) therapy]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2003:9554.
25. Cortelezzi A, Fracchiolla NS, Maisonneuve P, Moia M, Luchesini C, Ranzi ML, et al.Central venous catheter-related complications inpatients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures. Leukemia & Lymphoma 2003;44(9):1495-501.
26. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al.Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. Journal of Clinical Oncology 2005;23:4063-9.
27. Davenport C, University E, Briones M, Stockwell J. Impact of lovenox prophylaxis on the development of deep venous thrombosis in children with a central venous catheter. Conference: 40th Critical Care Congress of the Society of Critical Care Medicine San Diego. 2010:A219.
28. Deady A, Androkites A, Frederick E. [Indentification and management of thrombosis in pediatric patient with acute lymphoblastic leukemia receiving asparaginase therapy at Dana-Farber cancer institute]. Conference: 42nd Congress of the International Society of Pediatric Oncology, SIOP. 2010:984.
29. De Cicco M, Matovic M, Pacenzia R, Fantin D, Caserta M, Bortolussi R, et al.[Short-term acenocumarine (A) or dalteparine (D) for the prevention of central venous catheter-related thrombosis (CVCrT) in cancer patients. A randomized controlled study based on serial venographies]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2006:8549.
30. Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM. Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study. Journal of Clinical Oncology 2004;22:2718-23.
31. Dümichen MJ, Seeger K, Lode HN, Kühl JS, Ebell W, Degenhardt P, et al.Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. Journal of Hospital Infection 2012;80:304-9.
32. Eichinger S, Traby L, Kaider A, Quehenberger P, Kyrle PA. [Prevention of venous thrombosis in cancer patients: a randomized, double-blind study comparing two different dosages of low-molecular weight heparin]. Congress: American Society of Hematology annual meeting and exposition, ASH. 2008:1977.
33. Fagnani D, Franchi R, Porta C, Giordano M, Scanni A, Bertolini A, et al.[Antithrombotic prophylaxis (AP) and catheter-related infections in cancer patients (pts) carrying central venous devices (CVD): an observational study]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2006:18550.
34. Faranoush M, Vossough P, Alebouyeh M, Golpayegani MR, Hedayatiasl AA, Rafsanjani KA, et al.[Analysis of the thrombotic risk and coagulation factor in children with acute lymphoblastic leukemia]. Conference: 39th Congress of the International Society of Pediatric Oncology, SIOP. 2007:460.
35. Farge D, Bosquet L, Chahmi DK, Cajfinger F, Desmurs-Clavel H, Desruennes E, et al.2008 Guidelines for the treatment of venous thromboembolism in cancer patients: report from the French working group. Congress: American Society of Hematology annual meeting and exposition, ASH. 2008:1284.
36. Farhan SY, Vega J, Hanbali A, Kuriakose P, Janakiraman N. [Efficacy and safety of low dose versus full dose anticoagulation for prevention of thalidomide-related venous thromboembolism]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2008:19518.
37. Farinasso L, Bertorello N, Garbarini L, Gajno TM, Barisone E, Artesani L, et al.Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study. Leukemia 2007;21:552-6.
38. Ferreira Chacon JM, de Almeida EH, de Lourdes Simões R, Ozório VLC, Alves BC, de Andréa MLM, et al.Randomized study of minocycline and edetic acid as a locking solution for central line (Port-A-Cath) in children with cancer. Chemotherapy 2011;57:285-91.
39. Fratino G, Molinari AC, Parodi S, Longo S, Saracco P, Castagnola E, et al.Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Annals of Oncology 2005;16:648-54.
40. Freytes CO. Thromboembolic complications related to indwelling central venous catheters in children. Current Opinion in Oncology 2003;15:289-92.
41. Gabrail N, Sandler E, Charu V, Anas N, Lim E, Blaney M, et al.[A phase III, randomized double-blind, placebo-controlled study of tenecteplase for restoration of function in central venous catheters]. Congress: American Society of Hematology annual meeting and exposition, ASH. 2009:173.
42. Gerotziafas GT. Risk factors for venous thromboembolism in children. International Angiology 2004;23:195-205.
43. Giordano P, Del Vecchio GC, Saracco P, Zecca M, Molinari AC, De Mattia D. A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: recommendations of the "Coagulation Defects" AIEOP Working Group. Recent Patents on Cardiovascular Drug Discovery 2007;2:53-62.
44. Goldenburg NE, Pounder E, Knapp-Clevenger R, Manco-Johnson MJ. [Post-thrombotic syndrome affecting the upper venous system in children: validation of outcome measurement and application in a single-institutional prospective inception cohort study]. Congress: American Society of Hematology annual meeting and exposition, ASH. 2009:2979.
45. Goldenberg NE, Kahn S, Crowther MA, Kenet G, Nowak-Gottl U, Manco-Johnson MJ. [Post-thrombotic syndrome (PTS) in children: a systematic review of prevalence, validity of outcome measures, and prognostic factors]. Conference: American Society of Hematology annual meeting and exposition, ASH. 2009:2978.
46. Gonzalez G, Shochat SJ, Davidoff AM, Howard SC, Shenep JL, Rao BN, et al.[Central venous catheter placement in children with newly diagnosed acute leukemia: is early placement advisable?]. Conference: 42nd Congress of the International Society of Pediatric Oncology, SIOP. 2010:787.
47. Halton J, Nagel, K, Bradao L, Silva M, Gibson P, Chan A, et al.Do children with central venous line (CVL) dysfunction have increased risk of symptomatic thromboembolism compared to those without CVL-dysfunction, while on cancer therapy?. BioMed Central Cancer 2012;12:314.
48. Harney KM, McCabe M, Branowicki P, Kalish LA, Neufeld EJ. Observational cohort study of pediatric inpatients with centra venous catheter at "intermediate risk"of thrombosis and eligible for anticoagulant prophylaxis. Journal of Pediatric Oncology Nursing 2010;27(6):325-9.
49. Henrickson KJ, Axtell RA, Hoover SM, Kuhn SM, Pritchett J, Kehl SC, et al.Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial. Journal of Clinical Oncology 2000;18:1269-78.
50. Hoppensteadt D, Jeske W, Walenga J, Fareed J. [AVE5026: a new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2008:14653.
51. Kakkar VV, Balibrea J, Martinez-Gonzalez J, Prandoni P. Conference: 22nd Congress of the International Society on Thrombosis and Haemostasis, ISTH. 2009:LB-MO-002.
52. Kalmanti M, Germanakis J, Stiakaki E, Syfridaki C, Christidou A, Tsetis D, et al.Prophylaxis with urokinase in pediatric oncology patients with central venous catheters. Pediatric Hematology and Oncology 2002;19:173-9.
53. Kayton ML, Garmey EG, Ishill M, Cheung NKV, Kushner BH, Kramer K, et al.Preliminary results of a phase I trail of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections. Journal of Pediatric Surgery 2010;45:1961-6.
54. Kefeli U, Dane F, Yumuk PF, Karamanoglu A, Iyikesici S, Basaran G, et al.Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer. European Journal of Cancer Care 2009;18:191-4.
55. Kenney BD, David M, Bensoussan AL. Anticoagulation without catheter removal in children with catheter-related central vein thrombosis. Journal of Pediatric Surgery 1996;31:816-8.
56. Kethireddy S, Safdar N. Urokinase lock or flush solution for prevention of bloodstream infections associated with central venous catheters for chemotherapy: a meta-analysis of prospective randomized trials. The Journal of Vascular Access 2008;9:51-7.
57. Kovacs MJ, Andreou R, Rodger M, Anderson DR, Kahn SR, Mangel JE, et al.[A pilot study of central venous catheter survival in cancer patients using low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity (UEDVT)]. Congress: American Society of Hematology annual meeting and exposition, ASH. 2006:878.
58. Kuhle S, Spavor M, Massicotte P, Halton J, Cherrick I, Dix D, et al.Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia. Journal of Thrombosis and Haemostasis 2008;6:589-94.
59. Lee A, Parpia S, Julian J, Rickles F, Prins M, Levine M. [Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2009:9565.
60. Levine MN, Deitchman D, Julian J, Liebman H, Escalante C, O'Brien MC, et al.[A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2009:e20514.
61. Malowany JI, Monagle P, Knoppert DC, Lee DS, Wu J, McCusker P, et al.Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates. Thrombosis Research 2008;122:826-30.
62. Masroujeh R, Shamseddeen W, Isma'eel H, Otrock ZK, Khalil IM, Taher A. Underutilization of venous thromboembolism prophylaxis in medical patients in a tertiary care center. Journal of Thrombosis and Thrombolysis 2008;26:138-41.
63. Massicotte P, Julian JA, Marzinotto V, Gent M, Shields K, Chan AK, et al.Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thrombosis Research 2003;109:93-9.
64. Massicotte P, Mitchell L. Thromboprophylaxis of central venous lines in children with cancer: the first steps taken on the long road ahead. Acta Paediatrica 2006;95:1049-52.
65. Molinari AC, Haupt R, Saracco P, Di Marco M, Castagnola E, Fratino G. Urokinase for restoring patency of malfunctioning or blocked central venous catheters in children with hemato-oncological diseases. Supportive Care in Cancer 2004;12:840-3.
66. Möricke A, Zimmermann M, Greiner J, Schrauder A, Schmid H, Stanulla M, et al.[Prospective evaluation of thromboembolic events during chemotherapy of childhood acute lymphoblastic leukemia: results of randomized trial ALL-BFM 2000]. Congress: American Society of Hematology annual meeting and exposition, ASH. 2009:990.
67. Nguyen M, Goss D, Goss G, Nicholas GA. [Effect of prophylactic anticoagulation on thromboembolism associated with indwelling vascular catheters in patients with solid tumours: a review of the experience at a single centre.]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2008:20574.
68. Odabas H, Özdemir N, Abali H, Oksuzoglu B, Isik M, Civelek B, et al.[How frequently is subcutaneous central venous catheter care required to prevent luminal thrombosis]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2010:e19587.
69. Ragni MV, Journecake JM, Brambilla DJ. Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis. Haemophilia 2008;14:30-8.
70. Riess HB, Pelzer U, Opitz B, Hilbig A, Strauch M, Hahnfeld S. [A prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients]. Conference: 22nd Congress of the International Society on Thrombosis and Haemostasis, ISTH. 2009:LB-MO-003.
71. Rodenhuis S, van't Hek LG, Vlasveld LT, Kroger R, Dubbelman R, van Tol RG. Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator. Thorax 1993;48:558-9.
72. Ruud E, Holmstrom H, De Lange C, Natvig S, Albertsen BK, Wesenberg F. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study. Pediatric Hematology and Oncology 2006;23:207-16.
73. Savage KJ, Wells PS, Schulz V, Goudie D, Morrow B, Cruickshank M, et al.Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thrombosis and Haemostasis 1999;82:1008-10.
74. Schiavetti A, Matrunola M, Foco M, Ingrosso A, Varrasso G, Capocaccia P, et al.[Thrombosis in children with solid tumor]. Conference: 38th Congress of the International Society of Pediatric Oncology, SIOP. 2006:444.
75. Sharathkumar A, Southwood E, Fallon R, Heiny M. [Validation of post-thrombotic syndrome outcome scale for children with extremity and non-extremity venous thromboembolism]. Congress: American Society of Hematology annual meeting and exposition, ASH. 2010:3669.
76. Simmons GL, Hillner BE, Smith TJ. [An evaluation of the risk/benefit ratio of low molecular weight heparin to reduce the high risk of venous thromboembolism in acute leukemia]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2011:6566.
77. Simon A, Bode U, Lieber K, Beutel K, Fleischhack G. Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patients. American Journal of Infection Control 2008;36(1):54-8.
78. Simons WR, Choe Y, Powers A, McQueen C. [A real-world evaluation of the effectiveness of dalteparin in the prevention of recurrent venous thromboembolism compared to warfarin in patients with cancer]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2010:9115.
79. Skinner R, Koller K, McIntosh N, McCarthy A, Pizer B. Prevention and management of central venous catheter occlusion and thrombosis in children with cancer. Pediatric Blood and Cancer 2008;50:826-30.
80. Smith S, Dawson S, Hennessey R, Andrew M. Maintenance of the patency of indwelling central venous catheters: is heparin necessary?. American Journal of Pediatric Hematology/Oncology 1991;13:141-3.
81. Tassinari D, Scarpi E, Rupoli S, Leoni P. [Role of low molecular weight heparin (LMWH) in central venous catheter antithrombotic prophylaxis]. Conference: American Society of Clinical Oncology annual meeting proceedings, ASCO. 2007:9010.
82. Terrill KR, Lemons RS, Goldsby RE. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer. Journal of Pediatric Hematology/Oncology 2003;25:864-7.
83. Tesselaar ME, Ouwerkerk J, Nooy MA, Rosendaal FR, Osanto S. Risk factors for catheter-related thrombosis in cancer patients. European Journal of Cancer 2004;40:2253-9.
84. Traby L, Kaider A, Schmid R, Kranz A, Quehenberger P, Kyrle PA, et al.[Prevention of venous thrombosis in cancer patients: a prospective, randomized, double-blind study comparing two different dosages of low-molecular weight heparin]. Conference: 22nd Congress of the International Society on Thrombosis and Haemostasis, ISTH. 2009:PP-MO-422.
85. Trame MN, Mitchell L, Male C, Barrett J, Hempel G, Nowak-Gottl U. [Population pharmacokinetics of enoxaparin in children at risk for symptomatic thromboembolism]. Congress: American Society of Hematology annual meeting and exposition, ASH. 2009:1071.
86. Van Leeuwen Y, Gebuis EPA, Van der Meer FJM, Rosendaal FR. [A randomised comparison of the quality of anticoagulant therapy with two vitamin K antagonists: warfarin versus phenprocoumon]. Conference: 22nd Congress of the International Society on Thrombosis and Haemostasis, ISTH. 2009:LB-MO-001.
87. Verso M, Agnelli G, Gussoni G. [Prevention of thromboembolic events in advanced lung cancer patients receiving chemotherapy: a combined analysis from PROTECHT and topic-2 studies]. Conference: 22nd Congress of the International Society on Thrombosis and Haemostasis, ISTH. 2009:OC-MO-018.
88. Verso M, Agnelli G, Gussoni G. Prevention of thromboembolic events in advanced lung cancer patients receiving chemotherapy: a combined analysis from PROTECHT and topic-2 studies. Conference: 22nd Congress of the International Society on Thrombosis and Haemostasis, ISTH. 2009:OC-MO-018.
89. Yamashita A, Nagae C, Shoji T, Muto S, Asahara M, Morimoto M, et al.[Effects of asparaginase therapy on thrombin generation in children with acute leukemia]. Conference: 22nd Congress of the International Society on Thrombosis and Haemostasis, ISTH. 2009:PP-MO-439.
90. Young G, Boshkov L. Prospective study of direct thrombin inhibition with Argatroban in pediatric patients requiring nonheparin anticoagulation. Conference: American Society of Hematology, ASH. 2007:1868.
91. Young G, Yee DL, Khanna R, O'Brien S, Nugent D. [Fondaparinux for the treatment of thrombosis in children: a prospective, dose-finding, pharmacodynamic and safety study]. Congress: American Society of Hematology annual meeting and exposition, ASH. 2009:3130.
92. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, et al.Venous thromboembolic complications (VTE) in childrenfirst analyses of the Canadian Registry of VTE. Blood 1994;83(5):1251-7.
93. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thrombosis Research 2003;111(4-5):199-212.
94. Athale UH, Chan AKC. Thromboembolic complications in pediatric hematologic malignancies. Seminars in Thrombosis and Hemostasis 2007;33(4):416-26.
95. Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. The Journal of the American Medical Association 2005;293(6):715-22.
96. Brasseur B, Vermylen C, Hermans C. Impact of prophylactic administration of FFP on hypofibrinogenemia in paediatric patients treated with L-asparaginase for acute lymphoblastic leukaemia. Conference: International Society of Thrombosis and Haemostasis, ISTH. 2007:P-S-237.
97. Cunningham MS, White B, O'Donnell J. Prevention and management of venous thromboembolism in people with cancer: a review of the evidence. Clinical Oncology 2006;18(2):145-51.
98. Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD008500.pub2]
99. Goldenberg NA, Donadini MP, Kahn SR, Crowther M, Kenet G, Nowak-Göttl U, et al.Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica 2010;95(11):1952-9.
100. Harlev D, Zaidman I, Sarig G, Weyl Ben Arush M, Brenner B, Elhasid R. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thrombosis Research 2010;126:93-7.
101. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Archives of Internal Medicine 2000;160:809-15.
102. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011:www.cochrane-handbook.org.
103. Journeycake JM, Buchanan GR. Thrombotic complications of central venous catheters in children. Current Opinion in Hematology 2003;10(5):369-74.
104. Journeycake JM, Buchanan GR. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. Journal of Clinical Oncology 2008;24(28):4575-80.
105. Knofler R, Siegert E, Lauterbach I, Taut-Sack H, Siegert G, Gehrisch S, et al.Clinical importance of prothrombotic risk factors in pediatric patients with malignancyimpact of central venous lines. European Journal of Pediatrics 1999;158:S147-50.
106. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Seminars in Thrombosis and Hemostasis 1999;25(2):137-45.
107. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. The Journal of Pediatrics 1998;133(6):770-6.
108. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady N, et al.IDSA guidelines for the diagnosis and management of intravascular catheter-related bloodstream infections. Clinical Infectious Diseases 2009;49(11):1771-2.
109. Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, et al.Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 2010;115(24):4999-5004.
110. Kremer LCM, Van Dalen EC, Moher D, Caron HN. Cochrane Childhood Cancer Group. The Cochrane Library. Chichester: Wiley-Blackwell, 2010, Issue 4.
111. Molinari AC, Castagnola E, Mazzola C, Piacentino M, Fratino G. Thromboembolic complications related to indwelling central venous catheters in children with oncological/haematological diseases: a retrospective study of 362 catheters. Supportortive Care Cancer 2001;9:539-44.
112. Revel-Vilk S, Yacobovich J, Tamary H, Goldstein G, Nemet S, Weintraub M, et al.Risk factors for central venous catheter thrombotic complications in children and adolescents with cancer. Cancer 2010;116(17):4197-205.
113. Ruud E, Holmstrom H, Hopp E, Wesenberg F. Central line-associated venous late effects in children without prior history of thrombosis. Acta Paediatrica 2006;95(9):1060-5.
114. Stein PD, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, et al.Multidetector computed tomography for acute pulmonary embolism. New England Journal of Medicine 2006;354(22):2317-27.
115. The PIOPED investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The Journal of the American Medical Association 1990;263(20):2753-9.
116. Van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HSA, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. Journal of Pediatrics 2001;139(5):676-81.
117. Van Ommen CH, Heijboer H, Peters M. Management of venous thromboembolic disease in childhood. In: Van Beek EJR, Bller HR, Oudkerk M editor(s). Deep Vein Thrombosis and Pulmonary Embolism. First Edition. Chichester: Wiley-Blackwell, 2009:373-404.
118. Wilimas JA, Hudson M, Rao B, Luo X, Lott L, Kaste SC. Late vascular occlusion of central lines in pediatric malignancies. Pediatrics 1998;101(2):1-5.
119. Young G, Albisetti M, Bonduel M, Brandao L, Chan A, Friedrichs F, et al.Impact of inherited thrombophilia on venous thromboembolism in children. Circulation 2008;118:1373-82.
120. Zaunschirm A, Mutean W. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia. Pediatric Hematology and Oncology 1986;3:19-25.
121. Schoot RA, Kremer LCM, van de Wetering MD, van Ommen CH. Systemic treatments for the prevention of venous thrombo-embolic events in pediatric cancer patients with tunnelled central venous catheters. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD009160]